Literature DB >> 28585183

Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.

Sanjiv J Shah1.   

Abstract

There are few proven therapies for heart failure with preserved ejection fraction (HFpEF). The lack of therapies, along with increased recognition of the disorder and its underlying pathophysiology, has led to the acknowledgement that HFpEF is heterogeneous and is not likely to respond to a one-size-fits-all approach. Thus, HFpEF is a prime candidate to benefit from a precision medicine approach. For this reason, we have assembled a compendium of papers on the topic of precision medicine in HFpEF in the Journal of Cardiovascular Translational Research. These papers cover a variety of topics relevant to precision medicine in HFpEF, including automated identification of HFpEF patients; machine learning, novel molecular approaches, genomics, and deep phenotyping of HFpEF; and clinical trial designs that can be used to advance precision medicine in HFpEF. In this introductory article, we provide an overview of precision medicine in HFpEF with the hope that the work described here and in the other papers in this special theme issue will stimulate investigators and clinicians to advance a more targeted approach to HFpEF classification and treatment.

Entities:  

Keywords:  Cluster analysis; Heart failure with preserved ejection fraction; Machine learning; Precision medicine; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28585183      PMCID: PMC5540576          DOI: 10.1007/s12265-017-9756-y

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  59 in total

1.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes.

Authors:  Marica Bordicchia; Dianxin Liu; Ez-Zoubir Amri; Gerard Ailhaud; Paolo Dessì-Fulgheri; Chaoying Zhang; Nobuyuki Takahashi; Riccardo Sarzani; Sheila Collins
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

2.  Trends in prevalence and outcome of heart failure with preserved ejection fraction.

Authors:  Theophilus E Owan; David O Hodge; Regina M Herges; Steven J Jacobsen; Veronique L Roger; Margaret M Redfield
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

3.  Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals.

Authors:  Susan Cheng; Caroline S Fox; Martin G Larson; Joseph M Massaro; Elizabeth L McCabe; Abigail May Khan; Daniel Levy; Udo Hoffmann; Christopher J O'Donnell; Karen K Miller; Christopher Newton-Cheh; Andrea D Coviello; Shalender Bhasin; Ramachandran S Vasan; Thomas J Wang
Journal:  Am J Cardiol       Date:  2011-08-01       Impact factor: 2.778

4.  Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice.

Authors:  Nicholas N Hoke; Fadi N Salloum; David A Kass; Anindita Das; Rakesh C Kukreja
Journal:  Stem Cells       Date:  2012-02       Impact factor: 6.277

5.  Influence of sex and hormone status on circulating natriuretic peptides.

Authors:  Carolyn S P Lam; Susan Cheng; Karen Choong; Martin G Larson; Joanne M Murabito; Christopher Newton-Cheh; Shalender Bhasin; Elizabeth L McCabe; Karen K Miller; Margaret M Redfield; Ramachandran S Vasan; Andrea D Coviello; Thomas J Wang
Journal:  J Am Coll Cardiol       Date:  2011-08-02       Impact factor: 24.094

6.  Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.

Authors:  Jun Yin; Marian Kukucka; Julia Hoffmann; Anja Sterner-Kock; Juergen Burhenne; Walter E Haefeli; Hermann Kuppe; Wolfgang M Kuebler
Journal:  Circ Heart Fail       Date:  2011-01-07       Impact factor: 8.790

7.  Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies.

Authors:  Abigail May Khan; Susan Cheng; Martin Magnusson; Martin G Larson; Christopher Newton-Cheh; Elizabeth L McCabe; Andrea D Coviello; Jose C Florez; Caroline S Fox; Daniel Levy; Sander J Robins; Pankaj Arora; Shalender Bhasin; Carolyn S P Lam; Ramachandran S Vasan; Olle Melander; Thomas J Wang
Journal:  J Clin Endocrinol Metab       Date:  2011-08-17       Impact factor: 5.958

8.  Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure.

Authors:  Christopher Newton-Cheh; Martin G Larson; Ramachandran S Vasan; Daniel Levy; Kenneth D Bloch; Aarti Surti; Candace Guiducci; Sekar Kathiresan; Emelia J Benjamin; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Stefan Blankenberg; Frank Kee; Peter Nilsson; Xiaoyan Yin; Leena Peltonen; Erkki Vartiainen; Veikko Salomaa; Joel N Hirschhorn; Olle Melander; Thomas J Wang
Journal:  Nat Genet       Date:  2009-02-15       Impact factor: 38.330

9.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  Irbesartan in patients with heart failure and preserved ejection fraction.

Authors:  Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska
Journal:  N Engl J Med       Date:  2008-11-11       Impact factor: 91.245

View more
  23 in total

Review 1.  Basic Mechanisms of Diabetic Heart Disease.

Authors:  Rebecca H Ritchie; E Dale Abel
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

Review 2.  Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.

Authors:  Sanjiv J Shah
Journal:  J Cardiovasc Transl Res       Date:  2017-07-05       Impact factor: 4.132

Review 3.  Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction.

Authors:  Faraz S Ahmad; Yuan Luo; Ramsey M Wehbe; James D Thomas; Sanjiv J Shah
Journal:  Heart Fail Clin       Date:  2022-03-04       Impact factor: 3.179

Review 4.  Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.

Authors:  Dane Rucker; Jacob Joseph
Journal:  Curr Heart Fail Rep       Date:  2022-09-30

5.  Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials.

Authors:  Ravi B Patel; Sanjiv J Shah
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

6.  Targeted Therapeutics for Transthyretin Cardiac Amyloidosis.

Authors:  Sanjiv J Shah
Journal:  Circulation       Date:  2019-01-22       Impact factor: 29.690

7.  20th Annual Feigenbaum Lecture: Echocardiography for Precision Medicine-Digital Biopsy to Deconstruct Biology.

Authors:  Sanjiv J Shah
Journal:  J Am Soc Echocardiogr       Date:  2019-11       Impact factor: 5.251

8.  Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction.

Authors:  Anna Bobenko; André Duvinage; Meinhard Mende; Volker Holzendorf; Kathleen Nolte; Christoph Herrmann-Lingen; Lutz Binder; Hans-Dirk Düngen; Gerd Hasenfuss; Burkert Pieske; Rolf Wachter; Frank Edelmann
Journal:  Int J Cardiol Heart Vasc       Date:  2020-05-07

Review 9.  Effects of inorganic nitrate supplementation on cardiovascular function and exercise tolerance in heart failure.

Authors:  Scott K Ferguson; Mary N Woessner; Michael J Holmes; Michael D Belbis; Mattias Carlström; Eddie Weitzberg; Jason D Allen; Daniel M Hirai
Journal:  J Appl Physiol (1985)       Date:  2021-01-21

Review 10.  Artificial Intelligence, Machine Learning, and Cardiovascular Disease.

Authors:  Pankaj Mathur; Shweta Srivastava; Xiaowei Xu; Jawahar L Mehta
Journal:  Clin Med Insights Cardiol       Date:  2020-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.